The FDA also asked the panel to comment on whether there are sufficient data to recommend that telaprevir be used in specific populations, including African Americans and patients with cirrhosis. Phase III data for telaprevir and boceprevir have suggested that the Vertex drug may be more efficacious in African American HCV patients, who historically have lower SVR rates than other patients on standard of care.
Elsevier Global Medical News and "The Pink Sheet" are published by Elsevier.